Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

Thierry André, C. Boni, Lamia Mounedji-Boudiaf, +9

New England Journal of Medicine

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

Thierry André, C. Boni, Matilde Navarro, +8

Journal of Clinical Oncology

Surgical OncologyCancer ManagementPathologySurgeryOverall Survival +14

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

David Cunningham, Seppo Pyrhönen, R.D. James, +9

The Lancet

Gastrointestinal OncologyMedicineCancer ManagementColorectal CancerMetastatic Colorectal Cancer +4

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial

Tim Maughan, Jonathan A. Ledermann, C. Topham, +11

The Lancet

Mrc FocusSurgical OncologyDifferent StrategiesGastrointestinal OncologyMedicine +5

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

TS Maughan, RD James, DJ Kerr, +5

The Lancet

Palliative CareContinuous Palliative ChemotherapyGastrointestinal OncologyMedicineColorectal Cancer +5

Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years

Armand de Gramont, C. Boni, Matilde Navarro, +7

Journal of Clinical Oncology

Surgical OncologyFolfox4 RegimenCancer ManagementMosaic StudyPathology +14

Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years

Armand de Gramont, C. Boni, Matilde Navarro, +8

Journal of Clinical Oncology

Surgical OncologyCancer ManagementPathologyRelative RiskSurgery +16

Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy

Ian Chau, A. Norman, David Cunningham, +8

British Journal of Cancer

Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer

Matthew Cunningham, Sharadah Essapen, Hilary Thomas, +5

International Journal of Oncology

Tumor BiologyEgfr ExpressionMedicineImmunologyColorectal Cancer +11

Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients

Matthew Cunningham, Sharadah Essapen, Hilary Thomas, +5

International Journal of Oncology